Top

Supportive Care in Cancer

Published in:

01-09-2005 | Original Article

Use of complementary and alternative medicine by patients with urologic cancer: a prospective study at a single Japanese institution

Authors: Koji Yoshimura, Nobufumi Ueda, Kentaro Ichioka, Yoshiyuki Matsui, Akito Terai, Yoichi Arai

Published in: Supportive Care in Cancer | Issue 9/2005

Abstract

Objectives

We prospectively evaluated the prevalence and predictors of complementary medicine (CAM) use among Japanese patients with urologic cancer 1 year after diagnosis.

Patients and methods

A total of 349 patients with newly diagnosed urologic cancer answered a self-administered questionnaire on CAM use 1 year after diagnosis. General-health-related quality of life (GHQL) of the patients was also assessed at diagnosis and 1 year after diagnosis using the Medical Outcome Study Short Form-36 (SF-36). The overall prevalence, types of CAM used, and costs of CAM were assessed. The effects of several variables including GHQL at baseline and 1 year after treatment on the prevalence of use of CAM were evaluated.

Results

A total of 164 respondents (47%) admitted using some type of CAM, of which 73 (45%) had used multiple types. “Health food,” in particular extract from Agaricus blazei, was the most common type of CAM used. CAM users had significantly lower scores for social function, general health perception, and vitality domains than CAM non-users 1 year after diagnosis. This tendency was more marked in users of multiple types of CAM.

Conclusions

“Health food,” including extract from A. blazei, was the most commonly used CAM in Japan. The prevalence of CAM use did not differ between patients with prostate cancer and those with urologic cancer other than prostrate cancer. CAM users, especially those who used multiple types of CAM, had lower GHQL scores than non-users of CAM.

Eisenberg DM, Kessler RC, Foster C et al (1993) Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328:246–252CrossRefPubMed

Lippert MC, McClain R, Boyd JC et al (1999) Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86:2642–2648

Kao GD, Devine P (2000) Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88:615–619

Nam RK, Fleshner N, Rakovitch E et al (1999) Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 161:1521–1524CrossRefPubMed

Wilkinson S, Gomella LG, Smith JA et al (2002) Attitudes and use of complementary medicine in men with prostate cancer. J Urol 168:2505–2509CrossRefPubMed

Boon H, Westlake K, Stewart M et al (2003) Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 62:849–853CrossRefPubMed

Diefenbach MA, Hamrick N, Uzzo R et al (2003) Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol 170:166–169CrossRefPubMed

Ponholzer A, Struhal G, Madersbacher S (2003) Frequent use of complementary medicine by prostate cancer patients. Eur Urol 43:604–608

Hall JD, Bissonette EA, Boyd JC et al (2003) Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. BJU Int 91:603–607CrossRefPubMed

10.

Beebe-Dimmer JL, Wood DP Jr, Gruber SB et al (2004) Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology 63:282–287CrossRefPubMed

11.

Ware JE, Scherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 30:473–483PubMed

12.

Fukuhara S, Koshinski M (1998) Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol 51:1045–1053PubMed

13.

Yoshimura K, Ichioka K, Terada N et al (2003) Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. Int J Clin Oncol 8:26–30CrossRefPubMed

14.

Liu JM, Chu HC, Chin YH et al (1997) Cross sectional study of use of alternative medicines in Chinese cancer patients. Jpn J Clin Oncol 27:37–41

15.

Maskarinec G, Shumay DM, Kakai H et al (2000) Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 6:531–538PubMed

16.

Kim MJ, Lee SD, Kim DR et al (2004) Use of complementary and alternative medicine among Korean cancer patients. Korean J Intern Med 19:250–256PubMed

17.

Downer SM, Cody MM, NcCluskey P et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed

18.

Richardson MA, Sanders T, Palmer JL et al (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed

19.

Rees RW, Feigel I, Vickers A et al (2000) Prevalence of complementary therapy use by women with breast cancer: a population-based study. Eur J Cancer 36:1359–1364

20.

Paltiel O, Avitzour M, Peretz T et al (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed

21.

Mochen R, Kemmler G, Schweigkofler H et al (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274

22.

Burstein HJ, Gelber S, Guadagnoli E et al (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRefPubMed

23.

Carlsson M, Arman M, Backman M et al (2001) Perceived quality of life and coping for Swedish women with breast cancer who choose complementary medicine. Cancer Nurs 24:395–401CrossRefPubMed

24.

Cassileth BR, Lusk EJ, Guerry D et al (1991) Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med, 324:1180–1185PubMed

25.

Davidson R, Geoghegan L, McLaughlin L et al Psychological characteristics of cancer patients who use complementary therapies. Psycho Oncol, (in print)

Title: Use of complementary and alternative medicine by patients with urologic cancer: a prospective study at a single Japanese institution
Authors: Koji Yoshimura
Nobufumi Ueda
Kentaro Ichioka
Yoshiyuki Matsui
Akito Terai
Yoichi Arai
Publication date: 01-09-2005
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 9/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-005-0842-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2005

Development of a prognostic index in cancer patients with low performance status

Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain

Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma

CAM for cancer?

Society News September 2005

Correlation between “malfunctioning events” and catheter-related infections in pediatric cancer patients bearing tunneled indwelling central venous catheter: results of a prospective observational study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer